Cargando…

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer

Adjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT. This study aimed to identify these women using a molecular-based approach. METHODS: We analyzed two ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjöström, Martin, Fyles, Anthony, Liu, Fei-Fei, McCready, David, Shi, Wei, Rey-McIntyre, Katrina, Chang, S. Laura, Feng, Felix Y., Speers, Corey W., Pierce, Lori J., Holmberg, Erik, Fernö, Mårten, Malmström, Per, Karlsson, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022846/
https://www.ncbi.nlm.nih.gov/pubmed/36599119
http://dx.doi.org/10.1200/JCO.22.00655
_version_ 1784908807621574656
author Sjöström, Martin
Fyles, Anthony
Liu, Fei-Fei
McCready, David
Shi, Wei
Rey-McIntyre, Katrina
Chang, S. Laura
Feng, Felix Y.
Speers, Corey W.
Pierce, Lori J.
Holmberg, Erik
Fernö, Mårten
Malmström, Per
Karlsson, Per
author_facet Sjöström, Martin
Fyles, Anthony
Liu, Fei-Fei
McCready, David
Shi, Wei
Rey-McIntyre, Katrina
Chang, S. Laura
Feng, Felix Y.
Speers, Corey W.
Pierce, Lori J.
Holmberg, Erik
Fernö, Mårten
Malmström, Per
Karlsson, Per
author_sort Sjöström, Martin
collection PubMed
description Adjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT. This study aimed to identify these women using a molecular-based approach. METHODS: We analyzed two randomized trials of women with node-negative invasive breast cancer to ± RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no adjuvant systemic therapy) and Princess Margaret (age 50 years or older, T1-T2, adjuvant tamoxifen). Transcriptome-wide profiling was performed (Affymetrix Human Exon 1.0 ST microarray). Patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative tumors and with gene expression data were included. The SweBCG91-RT cohort was divided into training (N = 243) and validation (N = 354) cohorts. A 16-gene signature named Profile for the Omission of Local Adjuvant Radiation (POLAR) was trained to predict locoregional recurrence (LRR) using elastic net regression. POLAR was then validated in the SweBCG91-RT validation cohort and the Princess Margaret cohort (N = 132). RESULTS: Patients categorized as POLAR low-risk without RT had a 10-year LRR of 6% (95% CI, 2 to 16) and 7% (0 to 27) in SweBCG91-RT and Princess Margaret cohorts, respectively. There was no significant benefit from RT in POLAR low-risk patients (hazard ratio [HR], 1.1 [0.39 to 3.4], P = .81, and HR, 1.5 [0.14 to 16], P = .74, respectively). Patients categorized as POLAR high-risk had a significant decreased risk of LRR with RT (HR, 0.43 [0.24 to 0.78], P = .0055, and HR, 0.25 [0.07 to 0.92], P = .038, respectively). An exploratory analysis testing for interaction between RT and POLAR in the combined validation cohort was performed (P = .066). CONCLUSION: The novel POLAR genomic signature on the basis of LRR biology may identify patients with a low risk of LRR despite not receiving RT, and thus may be candidates for RT omission.
format Online
Article
Text
id pubmed-10022846
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-100228462023-03-18 Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer Sjöström, Martin Fyles, Anthony Liu, Fei-Fei McCready, David Shi, Wei Rey-McIntyre, Katrina Chang, S. Laura Feng, Felix Y. Speers, Corey W. Pierce, Lori J. Holmberg, Erik Fernö, Mårten Malmström, Per Karlsson, Per J Clin Oncol ORIGINAL REPORTS Adjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT. This study aimed to identify these women using a molecular-based approach. METHODS: We analyzed two randomized trials of women with node-negative invasive breast cancer to ± RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no adjuvant systemic therapy) and Princess Margaret (age 50 years or older, T1-T2, adjuvant tamoxifen). Transcriptome-wide profiling was performed (Affymetrix Human Exon 1.0 ST microarray). Patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative tumors and with gene expression data were included. The SweBCG91-RT cohort was divided into training (N = 243) and validation (N = 354) cohorts. A 16-gene signature named Profile for the Omission of Local Adjuvant Radiation (POLAR) was trained to predict locoregional recurrence (LRR) using elastic net regression. POLAR was then validated in the SweBCG91-RT validation cohort and the Princess Margaret cohort (N = 132). RESULTS: Patients categorized as POLAR low-risk without RT had a 10-year LRR of 6% (95% CI, 2 to 16) and 7% (0 to 27) in SweBCG91-RT and Princess Margaret cohorts, respectively. There was no significant benefit from RT in POLAR low-risk patients (hazard ratio [HR], 1.1 [0.39 to 3.4], P = .81, and HR, 1.5 [0.14 to 16], P = .74, respectively). Patients categorized as POLAR high-risk had a significant decreased risk of LRR with RT (HR, 0.43 [0.24 to 0.78], P = .0055, and HR, 0.25 [0.07 to 0.92], P = .038, respectively). An exploratory analysis testing for interaction between RT and POLAR in the combined validation cohort was performed (P = .066). CONCLUSION: The novel POLAR genomic signature on the basis of LRR biology may identify patients with a low risk of LRR despite not receiving RT, and thus may be candidates for RT omission. Wolters Kluwer Health 2023-03-10 2023-01-04 /pmc/articles/PMC10022846/ /pubmed/36599119 http://dx.doi.org/10.1200/JCO.22.00655 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle ORIGINAL REPORTS
Sjöström, Martin
Fyles, Anthony
Liu, Fei-Fei
McCready, David
Shi, Wei
Rey-McIntyre, Katrina
Chang, S. Laura
Feng, Felix Y.
Speers, Corey W.
Pierce, Lori J.
Holmberg, Erik
Fernö, Mårten
Malmström, Per
Karlsson, Per
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title_full Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title_fullStr Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title_full_unstemmed Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title_short Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
title_sort development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022846/
https://www.ncbi.nlm.nih.gov/pubmed/36599119
http://dx.doi.org/10.1200/JCO.22.00655
work_keys_str_mv AT sjostrommartin developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT fylesanthony developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT liufeifei developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT mccreadydavid developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT shiwei developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT reymcintyrekatrina developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT changslaura developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT fengfelixy developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT speerscoreyw developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT piercelorij developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT holmbergerik developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT fernomarten developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT malmstromper developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer
AT karlssonper developmentandvalidationofagenomicprofilefortheomissionoflocaladjuvantradiationinbreastcancer